Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia

A.P. Kater, M.H.J. van Oers, Y. van Norden, L. van der Straten, J. Driessen, W.F.M. Posthuma, M. Schipperus, M.E.D. Chamuleau, M. Nijland, J.K. Doorduijn, M. Van Gelder, M. Hoogendoorn, F. De Croon, S. Wittebol, J.M. Kerst, E.W.A. Marijt, R.A.P. Raymakers, M.R. Schaafsma, J.A. Dobber, S. KerstingM.D. Levin

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)147-154
Number of pages8
JournalHaematologica-the Hematology Journal
Volume104
Issue number1
DOIs
Publication statusPublished - 1 Jan 2019

Keywords

  • cll
  • diagnosis
  • guidelines
  • initial therapy
  • multicenter
  • obinutuzumab
  • phase-ii
  • previously untreated patients
  • trial
  • update
  • DIAGNOSIS
  • MULTICENTER
  • CLL
  • GUIDELINES
  • PHASE-II
  • PREVIOUSLY UNTREATED PATIENTS
  • TRIAL
  • INITIAL THERAPY
  • UPDATE
  • OBINUTUZUMAB

Cite this